MRK supply chain intelligence for Merck & Co., Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 92% | Reblozyl is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb Company (BMS) |
| BMY | Bristol-Myers Squibb Company | 92% | Reciprocal relationship from BMY graph: Reciprocal relationship from MRK graph: Reblozyl is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a glo… |
| HBIO | Harvard Bioscience, Inc. | 92% | Reciprocal relationship from HBIO graph: Our pharmaceutical and biotechnology customers include companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johns… |
| INTS | Intensity Therapeutics, Inc. | 92% | Reciprocal relationship from INTS graph: In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Me… |
| CIDARA | CIDARA | 90% | Merck acquired Cidara, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $ 9.2 billion |
| DAIICHI-SANKYO | DAIICHI-SANKYO | 90% | Merck is working with Daiichi Sankyo to address FDA feedback |
| J-J-INNOVATIVE-MEDICINE | J-J-INNOVATIVE-MEDICINE | 90% | Under a previous license agreement between Cidara and J&J Innovative Medicine...J&J Innovative Medicine is eligible to receive up to $ 105 million in regulatory milestones and up to $ 455 million in … |
| NEUP | Neuphoria Therapeutics Inc. | 85% | Reciprocal relationship from NEUP graph: the Carina Biotech License, and $67.9 million from Australian research and development credits and government grants and assistance. |
| PSNL | Personalis, Inc. | 85% | Reciprocal relationship from PSNL graph: he sale of its equity securities and cash from operations. million was reclassified from accumulated other comprehensive loss to net loss within Other income … |
| THIRD-PARTY | THIRD-PARTY | 85% | The Company is working to reduce its Scope 3 emissions through a robust supplier engagement approach to drive collaboration upstream and downstream in its value chain |
| VERONA-PHARMA | VERONA-PHARMA | 85% | Animal health sales growth was due to the performance of both livestock and companion animal products. (which was obtained as part of the October 2025 acquisition of Verona Pharma plc [Verona Pharma]). |
| BNBX | BNB Plus Corp. | 72% | Reciprocal relationship from BNBX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BNBX gra… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our work… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph:… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EDSA gra… |
| ELAN | Elanco Animal Health Incorporated | 72% | Reciprocal relationship from ELAN graph: utical production processes are complex, highly regulated and can vary widely from product to product. Shifting or adding manufacturing capacity can be a leng… |
| ENZN | Viskase Companies, Inc. | 72% | Reciprocal relationship from ENZN graph: llion and $ 46.5 million, respectively. Revenue Recognition Royalty revenues from the Company’s agreements with third parties and pursuant to the sale of the … |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clinical trials. In the event of unstable ma… |
| EVFM | Evofem Biosciences, Inc. | 72% | Reciprocal relationship from EVFM graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain ou… |
| EXOZ | eXoZymes, Inc. | 72% | Reciprocal relationship from EXOZ graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EXOZ graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EXOZ gra… |
| GYRE | Gyre Therapeutics, Inc. | 72% | Reciprocal relationship from GYRE graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GYRE gra… |
| HRTX | Heron Therapeutics, Inc. | 72% | Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multi… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industri… |
| IBRX | ImmunityBio, Inc. | 72% | Reciprocal relationship from IBRX graph: ese other potential products. We expect to invest heavily in our other current product candidates and in any future product candidates that we may develop. Ou… |
| MCUJF | Medicure Inc. | 72% | Reciprocal relationship from MCUJF graph: ces performed by the Company’s customers, including the amount of such payment; · the Federal False Claims Act, which imposes civil and criminal liability on… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MGNX gra… |
| MRNA | Moderna, Inc. | 72% | Reciprocal relationship from MRNA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MRNA gra… |
| NUVL | Nuvalent, Inc. | 72% | Reciprocal relationship from NUVL graph: rers must also establish registration and device listings with the FDA. A medical device manufacturer’s manufacturing processes and those of its suppliers are… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | 90% | Reciprocal relationship from JANX graph: Merck has the unilateral right to terminate the agreement in its entirety or on a Collaboration Target by Collaboration Target basis at any time and for any r… |
| OGN | Organon & Co. | 90% | Reciprocal relationship from OGN graph: Oss, Netherlands Women’s health Pandaan, Indonesia Cardiovascular, respiratory and dermatology Xochimilco, Mexico Cardiovascular and respiratory Most of our in… |
| THIRD-PARTY | THIRD-PARTY | 90% | Merck paid an additional 7% royalty on worldwide sales of Gardasil/Gardasil 9 to another third party |
| OGN | Organon & Co. | 85% | n ADC and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on f… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BMY graph: Reciprocal relationship from MRK graph: es will equally share expenses as well … |
| BMY | Bristol-Myers Squibb Company | 72% | es will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights, and Merck will receive a % sales-based royalty. Merck will record its share… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from MRK graph: es will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive r… |
| BMYMP | Bristol-Myers Squibb Co | 72% | es will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights, and Merck will receive a % sales-based royalty. Merck will record its share… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CAH graph:… |
| CAH | Cardinal Health, Inc. | 72% | . Includes cumulative translation adjustments. Amount in 2025 includes the reversal of $ million for a Zerbaxa (ceftolozane and tazobactam) sales-based milestone as it was determined that payment was… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS gra… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cG… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary … |
| ELAN | Elanco Animal Health Incorporated | 72% | Reciprocal relationship from ELAN graph: utical production processes are complex, highly regulated and can vary widely from product to product. Shifting or adding manufacturing capacity can be a leng… |
| ELAN | Elanco Animal Health Incorporated | 72% | net sales of MK-1045, if approved. In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco aqua business) for total consideration of $ 1.3 billion. The Elanco aqua… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: bstantial amounts to continue the development of our GD-T cell-based therapeu… |
| EVFM | Evofem Biosciences, Inc. | 72% | Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely dev… |
| EXOZ | eXoZymes, Inc. | 72% | Reciprocal relationship from EXOZ graph: ● predictable, single-product precision without undesired by-products. The technology delivers >99% food/pharma-grade purity, simplifying formulation and regu… |
| GLSI | Greenwich LifeSciences, Inc. | 72% | Reciprocal relationship from GLSI graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GLSI gra… |
| HOWL | Werewolf Therapeutics, Inc. | 72% | Reciprocal relationship from HOWL graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL gra… |
| HRTX | Heron Therapeutics, Inc. | 72% | Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multi… |
| IBRX | ImmunityBio, Inc. | 72% | Reciprocal relationship from IBRX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from IBRX graph: ese other potential products. We expect to invest heavily in our other curren… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from MRK graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from MRK graph: nd in the U.S. driven primarily by decl… |
| JNJ | Johnson & Johnson | 72% | nd in the U.S. driven primarily by declining COVID-19 cases. The Company expects the Lagevrio sales decline to continue in 2026. Immunology ($ in millions) 2025 % Change % Change Excluding Foreign Ex… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MCK graph: Reciprocal relationship from MRK graph: . Includes cumulative translation adjus… |
| MCK | McKesson Corporation | 72% | . Includes cumulative translation adjustments. Amount in 2025 includes the reversal of $ million for a Zerbaxa (ceftolozane and tazobactam) sales-based milestone as it was determined that payment was… |
| MCUJF | Medicure Inc. | 72% | Reciprocal relationship from MCUJF graph: o the Company and its business can be found in the “Risk Factors” section of this Annual Report. 3 Table of Contents PART I ITEM 1. IDENTITY OF DIRECTORS, SE… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Furt… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MRK-DEBT | Debt stack $49.1B | 90% | Market cache reports total debt of $49.1B. |
| MRK-DEBT-6901 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2010-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MRK-OWNER-MERCK-CO-INC | Merck & Co., Inc. | 90% | 13F overlay lists Merck & Co., Inc. as top holder; 1 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | ['customer', 'supplier'] |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| EXOZ | eXoZymes, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| RXRX | Recursion Pharmaceuticals, Inc. | 100.00 | 2 |